Invivyd, Inc.
VYD2311
COVID-19
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews VYD2311 for COVID-19 around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“VYD2311 Pediatric Study Final protocol submitted to FDA Aligned with FDA on Initial Pediatric 3 Arms: Study Plan to support BLA filing (1) VYD2311 (2) mRNA Vax (3) VYD2311+mRNA Vax Plan for single study to assess the immunogenicity Operatio”